Blood-brain barrier transport mechanisms for antibody therapeutics — Analysis Notebook

CI-generated notebook stub for analysis sda-2026-04-01-gap-008. Anti-amyloid antibodies (lecanemab, donanemab) have ~0.1% brain penetrance. Engineering improved BBB transcytosis via transferrin receptor, LRP1, or novel shuttle peptides could dr

📊 Related Analysis: Blood-brain barrier transport mechanisms for antibody therapeutics (neurodegeneration)
Created: 2026-04-16
Download .ipynb